These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 12601370)
1. Antiviral therapy in HBe-Ag-positive hepatitis B with normal aminotransferase levels. Geier A; Dietrich CG; Gartung C Hepatology; 2003 Mar; 37(3):712-3; author reply 713. PubMed ID: 12601370 [No Abstract] [Full Text] [Related]
2. Monitoring of HBe antigen and alanine aminotransferase levels in hepatitis B virus DNA positive patients. Imtiaz F; Abbas Z; Moatter T J Coll Physicians Surg Pak; 2005 Feb; 15(2):103-4. PubMed ID: 15730837 [No Abstract] [Full Text] [Related]
3. Hepatitis B e antigen-negative patients with persistently normal alanine aminotransferase levels and hepatitis B virus DNA > 2000 IU/mL. Dai CY; Chuang WL; Huang JF; Yu ML Hepatology; 2009 Feb; 49(2):704-5; author reply 705-6. PubMed ID: 19177587 [No Abstract] [Full Text] [Related]
4. A call for attention and trials on hepatitis B e antigen-negative, alanine aminotransferase-normal chronic hepatitis B virus infection. Zhao H; Miao R Hepatology; 2009 Aug; 50(2):658; author reply 658-9. PubMed ID: 19585650 [No Abstract] [Full Text] [Related]
5. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901 [TBL] [Abstract][Full Text] [Related]
6. Designing studies to evaluate anti-hepatitis B virus therapies: from the perspective of studies for the registration of pharmaceutical products. Murray AB Methods Mol Med; 2004; 96():445-56. PubMed ID: 14762286 [No Abstract] [Full Text] [Related]
7. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. Suzuki Y; Kobayashi M; Ikeda K; Suzuki F; Arfase Y; Akuta N; Hosaka T; Saitoh S; Kobayashi M; Someya T; Matsuda M; Sato J; Watabiki S; Miyakawa Y; Kumada H J Med Virol; 2005 May; 76(1):33-9. PubMed ID: 15779048 [TBL] [Abstract][Full Text] [Related]
8. Should antiviral treatment be extended to patients with chronic hepatitis B and mildly elevated alanine aminotransferase? Lok AS Hepatology; 2010 Apr; 51(4):1107-9. PubMed ID: 20162620 [No Abstract] [Full Text] [Related]
9. Reactivation of hepatitis B virus in an inactive hepatitis B carrier with glucocorticoid pulse therapy. Tseng TC; Liu CJ; Hsieh SC; Chen PJ; Lai MY; Chen DS; Kao JH Dig Liver Dis; 2009 Apr; 41(4):322-3. PubMed ID: 18848814 [No Abstract] [Full Text] [Related]
10. Viral load in hepatitis B e antigen-negative carriers with normal aminotransferase level. Liaw YF Hepatology; 2007 Sep; 46(3):947; author reply 947-9. PubMed ID: 17705263 [No Abstract] [Full Text] [Related]
11. The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B. Shindo M; Hamada K; Nishioji K; Muramatsu A; Oda Y; Okuno T J Gastroenterol; 2004; 39(3):260-7. PubMed ID: 15065004 [TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT*. Sarin SK; Sandhu BS; Sharma BC; Jain M; Singh J; Malhotra V J Viral Hepat; 2004 Nov; 11(6):552-8. PubMed ID: 15500556 [TBL] [Abstract][Full Text] [Related]
13. [Lamivudine treatment for hepatitis B]. Lamivudine Clincal Practice Group Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):425-8. PubMed ID: 15487066 [No Abstract] [Full Text] [Related]
14. Treatment of HBeAg-positive patients with nucleos/tide analogues. Coffin CS; Lee SS Liver Int; 2009 Jan; 29 Suppl 1():116-24. PubMed ID: 19207974 [TBL] [Abstract][Full Text] [Related]
15. Molecular and serological characterization of hepatitis B virus in deferred Ghanaian blood donors with and without elevated alanine aminotransferase. Candotti D; Opare-Sem O; Rezvan H; Sarkodie F; Allain JP J Viral Hepat; 2006 Nov; 13(11):715-24. PubMed ID: 17052270 [TBL] [Abstract][Full Text] [Related]
16. Virus-specific T cell immune response in children and adolescents with chronic hepatitis B virus infection. Fischler B; Nyström J; Björnsdottir T; Lindh G; Hultgren C J Pediatr Gastroenterol Nutr; 2007 Jul; 45(1):75-83. PubMed ID: 17592368 [TBL] [Abstract][Full Text] [Related]
17. [Chronic hepatitis B virus (HBV) infection: usefulness of the combination of HBeAg and ALT determination to predict a high HBV-DNA level and therefore the necessity of referral to a specialist for possible antiviral treatment]. Veldhuijzen IK; Mostert MC; Niesters HG; Richardus JH; de Man RA Ned Tijdschr Geneeskd; 2008 Jun; 152(25):1426-30. PubMed ID: 18624006 [TBL] [Abstract][Full Text] [Related]
18. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011 [TBL] [Abstract][Full Text] [Related]
19. Clinical trial results and treatment resistance with lamivudine in hepatitis B. Wright TL Semin Liver Dis; 2004; 24 Suppl 1():31-6. PubMed ID: 15192799 [TBL] [Abstract][Full Text] [Related]
20. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]